Malaria Clinical Trial
— SHP2Official title:
Star Homes - Better Health Through Better Housing: Phase 2 House Evaluation
Malaria, pneumonia and diarrhoea causes a lot of illness in children in Tanzania and the study want to find better ways of protecting people against these diseases and want to find out if the type of house design can affect the general health of children living in the house.
Status | Recruiting |
Enrollment | 2750 |
Est. completion date | December 31, 2025 |
Est. primary completion date | January 3, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A to 12 Years |
Eligibility | Inclusion Criteria Main study - Children, aged under 13 years old, male or female - Residing in a study village for at least 3 years - Parents/guardian is willing and able to give written informed consent for the child to participate in the baseline and end-of study evaluation and the surveillance for malaria, respiratory tract infection and diarrhoeal disease. - Additionally, children 10, 11, and 12 years of age provide assent to participate. Ancillary studies - Head of a household or other family member of a household that is taking part in the main study - 18 years and above - Consent to take part in the main study - Residing and live in the village for 3 years or more - Live in the intervention or comparison houses or a trusted community member (community leaders, medical officer and community health worker) Exclusion criteria Main study - Any participant who refuses, or in the case of children whose parents/guardian refuses, to participate in the study. - Any child who is between 10 and 12 years who refuses to provide assent - If the family plans for moving to other village during the study period - Parents/guardians have mental health problems Ancillary studies - Under 18 years - Not provide consent - Not living in the study village for 3 years or more |
Country | Name | City | State |
---|---|---|---|
Tanzania | CSK Research Solutions | Dar Es Salaam | Mtwara |
Lead Sponsor | Collaborator |
---|---|
University of Oxford | CSK Research Solutions, Mahidol Oxford Tropical Medicine Research Unit |
Tanzania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of malaria in children under 13 years of age. | The incidence per year of malaria in children under 13 years old. | Approximately 3 years | |
Primary | Incidence of respiratory tract disease in children under 13 years of age. | The incidence per year of respiratory tract disease in children under 13 years old. | Approximately 3 years | |
Primary | Incidence of diarrhoeal disease in children under 13 years of age. | The incidence per year of diarrhoeal disease in children under 13 years old. | Approximately 3 years | |
Secondary | Mean number of female An. gambiae s.l. | Mean number of female An. gambiae s.l./light trap/night | Approximately 3 years | |
Secondary | Mean number of flies | Mean number of flies/sticky trap/week in kitchens of the houses | Approximately 3 years | |
Secondary | Entomological inoculation rate of malaria vectors. | Compare entomological inoculation rate of mosquito inside novel and traditional rural houses. | Approximately 3 years | |
Secondary | Children requiring hospital admission | Compare hospitalization rate of children under 13 years living inside novel and traditional rural houses. | Approximately 3 years | |
Secondary | Major respiratory pathogens | From children requiring hospital admission, the most frequently detected respiratory tract pathogens will be assessed through blood culture. | Approximately 3 years | |
Secondary | Major enteric pathogens | From children requiring hospital admission, the most frequently detected enteric pathogens will be assessed through rotavirus ELISA testing and bacterial culture of stool specimens. | Approximately 3 years | |
Secondary | Prevalence of malaria parasitaemia among children living in novel design houses and traditional homes. | Prevalence will be assessed from a cross-sectional surveys of children, based on dried blood smears will be collected for quantitative polymerase chain reaction once per quarter. | Approximately 3 years | |
Secondary | Mean changes in weight | Weight in kilograms of children under 13 years of age recorded at baseline, annually and at end of the study. | Approximately 3 years | |
Secondary | Mean changes in height | Height in meters of children under 13 years of age recorded at baseline, annually and at end of the study. | Approximately 3 years | |
Secondary | Mean changes in body mass index (BMI) | BMI in Kg/m2 in meters of children under 13 years of age recorded at baseline, annually and at end of the study. | Approximately 3 years | |
Secondary | Mean changes in mid-upper arm circumference | Mid-upper arm circumference in millimeters of children under 13 years of age recorded at baseline, annually and at end of the study. | Approximately 3 years | |
Secondary | Disease severity | A subgroup analysis of children requiring hospital consultation and children requiring hospitalization. | Approximately 3 years | |
Secondary | Indoor temperature | Temperature will be measured using data loggers. | Approximately 2 years | |
Secondary | Humidity | Humidity will be measured using data loggers. | Approximately 2 years | |
Secondary | Carbon dioxide (CO2) | Carbon dioxide (CO2) will be measured using data loggers. | Approximately 2 years | |
Secondary | Particulate matter 2.5 (PM2.5) particle pollution | PM2.5 particle pollution will be measured using data loggers. | Approximately 2 years | |
Secondary | Acceptability of the novel design houses. | The acceptability will be measured through a mixed method: 1) quantitative method i.e. closed ended questions with a pre-determined set of choices 2) qualitative method i.e. open ended questions through focused group discussions and in-depth interviews. | Interviews at 6 months after moving in, 1 year and at the end of the study | |
Secondary | Bednet use | Assessed by asking residents and in children with less than 5 years old in traditional and novel design homes regarding the use of insecticide treated bednets. | Annually (for three years) | |
Secondary | Life-cycle analysis | This is the cost of illness averted by living in a novel-designed home against a background of complete coverage with insecticide-treated nets. The analysis will include cost comparison (construction and maintenance of novel and control houses) and market analysis. | Over 36 months period starting from moving in date. | |
Secondary | Durability | Yearly inspections of houses (control and intervention). Maintenance of structural problems on demand. | End of year 1, 2 and 3. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |